Last updated: February 20, 2026
What is the scope of patent EP2334178?
The European patent EP2334178, granted to Vanda Pharmaceuticals Inc., claims a specific pharmaceutical composition and its use, focused on a novel formulation for treating central nervous system (CNS) disorders. The patent covers a crystalline form of iloperidone, a second-generation antipsychotic drug, with particular emphasis on its polymorphic form and improved bioavailability.
Key Features:
- Polymorphic crystalline form of iloperidone
- Intended for improved stability and bioavailability
- Applicable for treatment of psychosis, schizophrenia, and related CNS disorders
The patent's scope primarily encompasses the crystalline polymorph, its preparation methods, and its use in pharmaceutical compositions.
What are the key claims of EP2334178?
The claims define the legal scope, focusing on two main categories: the crystalline form and its pharmaceutical applications.
Claim Breakdown:
| Claim Type |
Description |
Specifics |
| Product Claims |
Crystalline polymorph of iloperidone |
Characterized by X-ray diffraction pattern, melting point, and spectroscopic features. |
| Process Claims |
Methods of preparing the crystalline polymorph |
Specific solvents, temperatures, and process conditions used in synthesis. |
| Use Claims |
Use of the crystalline form in treatment methods |
Indication for treatment of schizophrenia, psychosis, or related disorders. |
| Formulation Claims |
Pharmaceutical compositions |
Tablets, capsules, and injectable forms containing the crystalline form. |
Notable claim attributes:
- Polymorph characterization: A unique X-ray diffraction peak at 2θ around 12.4°, ensuring specific crystalline structure.
- Process features: Use of solvents such as ethanol or isopropanol, with recrystallization at controlled temperatures.
- Therapeutic use: Treating schizophrenia with a composition comprising the crystalline form.
Claims are written to secure protection over the specific polymorph, its manufacturing process, and its pharmaceutical applications, limiting potential design-around alternatives to forms not falling within these parameters.
What is the patent landscape surrounding EP2334178?
The patent landscape features several competing patents and patent families, primarily centered on iloperidone and similar polymorphs. Notable related patents include:
Key patents and patent families:
- US patent US7815577: Claims crystalline forms of iloperidone with overlapping features.
- WO2011060418: Focuses on pharmaceutical compositions of iloperidone, including polymorphic forms.
- EP2362459: Covers different polymorphs of iloperidone, with differing X-ray diffraction signatures.
- US Patent US8324549: Relates to formulations with controlled release properties.
Landscape characteristics:
- Polymorph diversity: Multiple crystalline forms have been explored and patented, with distinctions often based on X-ray diffraction patterns and physical properties.
- Synthetic methods: Several patents describe synthesis processes, including recrystallization, solvent selection, and temperature control.
- Therapeutic claims: While some patents focus on compositions for schizophrenia, others target specific delivery systems or formulations.
Patent overlap and freedom to operate:
- EP2334178's claims are specific to a crystalline polymorph with defined structural features. Competitors with formulations based on different polymorphs or manufacturing methods may avoid infringement.
- The presence of multiple patents on crystalline forms suggests a crowded landscape, requiring careful freedom-to-operate analysis for derivative or alternative forms.
Geographical patent protections:
- US and EP filings are dominant, with some filings extending to Asian jurisdictions.
- Patent term expiry is generally 20 years from filing, with some patents pending extensions or patent term adjustments.
How does EP2334178 compare with prior art?
The patent gains novelty and inventive step over prior art, notably due to its specific crystalline characterization.
| Aspect |
EP2334178 |
Prior Art (e.g., US7815577, WO2011060418) |
Difference |
| Crystalline form |
Specific polymorph characterized by X-ray pattern |
Broader or different polymorphs |
Structural feature distinctive to EP2334178 |
| Process |
Recrystallization under specific conditions |
Varies, often less specific |
Adds specificity to manufacturing process |
| Use |
Treatment of schizophrenia with specific crystalline form |
Generally broad, may lack detailed polymorphs |
Narrower, more protected claims |
The patent's claims are sufficiently distinct in identifying the precise crystalline form, bolstering standing against prior art.
Key considerations for patent strategy:
- Due to overlapping patents on iloperidone polymorphs, freedom to operate hinges on the specific crystalline form protected.
- The process claims provide some barrier for alternative synthesis routes.
- The therapeutic claims are broad but depend on the crystalline form matching the patent's specifications.
Key Takeaways
- EP2334178 protects a specific crystalline polymorph of iloperidone, with emphasis on its structural and manufacturing features.
- The scope is narrow to this form but includes methods to produce it and uses in CNS disorder treatment.
- The patent landscape includes multiple overlapping patents on iloperidone polymorphs, requiring precise analysis for freedom to operate.
- Competitors may develop alternative polymorphs or formulations outside the scope of this patent to avoid infringement.
- The patent's protection generally extends until at least 2032, depending on filings and extensions.
FAQs
Q1: Can a different crystalline form of iloperidone infringe on EP2334178?
A1: Yes, if the new form's X-ray diffraction pattern, melting point, or spectroscopic features significantly overlap with those claimed in EP2334178, it risks infringement.
Q2: Are process patents more vulnerable to design-around strategies?
A2: Yes, patents covering methods of production can often be circumvented by alternative synthesis routes not covered by the claims.
Q3: How does the polymorphic form affect drug bioavailability?
A3: Polymorphs influence solubility and dissolution rate, directly impacting bioavailability. The crystalline form claimed in EP2334178 aims to improve these parameters.
Q4: What jurisdictions provide patent protection for EP2334178?
A4: European Patent Convention (EPC) jurisdictions, with equivalents or extensions potentially filed in the US, Japan, China, and other regions.
Q5: What are the main challenges in patenting crystalline forms?
A5: Demonstrating novelty and inventive step based on structural and physicochemical properties; avoiding prior art that discloses similar polymorphs.
References
[1] European Patent Office. (2023). EP2334178 patent document.
[2] U.S. Patent and Trademark Office. (2010). US7815577 patent.
[3] World Intellectual Property Organization. (2011). WO2011060418 patent.
[4] European Patent Office. (2012). EP2362459 patent.
[5] U.S. Patent and Trademark Office. (2012). US8324549 patent.
